Align TechnologyALGN
About: Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Employees: 21,690
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.52% more ownership
Funds ownership: 86.67% [Q3] → 87.19% (+0.52%) [Q4]
5% less funds holding
Funds holding: 715 [Q3] → 680 (-35) [Q4]
10% less first-time investments, than exits
New positions opened: 95 | Existing positions closed: 106
17% less capital invested
Capital invested by funds: $16.4B [Q3] → $13.6B (-$2.86B) [Q4]
24% less repeat investments, than reductions
Existing positions increased: 204 | Existing positions reduced: 270
43% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 4 (-3) [Q4]
48% less call options, than puts
Call options by funds: $163M | Put options by funds: $313M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Wells Fargo Vik Chopra 83% 1-year accuracy 10 / 12 met price target | 34%upside $255 | Overweight Initiated | 14 Feb 2025 |
Evercore ISI Group Elizabeth Anderson 51% 1-year accuracy 18 / 35 met price target | 37%upside $260 | Outperform Maintained | 6 Feb 2025 |
Morgan Stanley Erin Wright 50% 1-year accuracy 14 / 28 met price target | 43%upside $272 | Overweight Maintained | 6 Feb 2025 |
Piper Sandler Jason Bednar 45% 1-year accuracy 17 / 38 met price target | 42%upside $270 | Overweight Maintained | 6 Feb 2025 |
Jefferies Brandon Couillard 14% 1-year accuracy 3 / 22 met price target | 37%upside $260 | Buy Maintained | 23 Jan 2025 |
Financial journalist opinion
Based on 14 articles about ALGN published over the past 30 days
